GlassScriptPhysician profile
Nina Smelley
NPI 1275163503
$2,660.03
in general payments reported to CMS, 2019-2025
19 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,076 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $581.19 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $414.21 | 2024-2025 | Airsupra, Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $288.95 | 2024-2025 | |
| Amgen INC. | $276.21 | 2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $249.37 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Sumitomo Pharma America, INC. | $159.01 | 2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $127.04 | 2024-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $112.45 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.33 | 2024-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $67.52 | 2025 | |
| Insulet Corporation | $46.11 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.61 | 2024-2025 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $40.44 | 2024 | Yupelri |
| Exact Sciences Corporation | $37.96 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $36.64 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $32.64 | 2024 | Korlym |
| Pfizer INC. | $17.31 | 2025 | |
| Glaxosmithkline, LLC. | $17.04 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $14.00 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Smelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.